发明名称 Glycation cross-link breakers to increase resistance to enzymatic degradation
摘要 The present invention relates to a method to treat a grafts, implant, scaffold, and constructs, including allografts, xenografts, autografts, and prosthetics comprising collagen, with an inhibitor of collagen cross-links and/or advanced glycation endproducts (AGE), in order to alleviate the mechanical weakness induced by the cross-links. The invention also provides for kits for use in the operating theater during autograft, allograft or xenograft procedures, or for preparing allograft, xenografts or prosthetics that have not been already treated prior to packaging. The kit comprises a first agent or agents that inhibit collagen cross-links and/or advanced glycation endproducts, instructions for use, optionally a wash or rinse agent, and a device for containing the graft and first agent.
申请公布号 US9309304(B2) 申请公布日期 2016.04.12
申请号 US201313895527 申请日期 2013.05.16
申请人 CORNELL UNIVERSITY;NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY 发明人 Bourne Jonathan W.;Torzilli Peter A.
分类号 A61K38/39;A61K8/91;C07K14/78;A61K38/00 主分类号 A61K38/39
代理机构 Leason Ellis LLP 代理人 Leason Ellis LLP
主权项 1. A method of breaking, removing and/or eliminating advanced glycation end-product cross-links in collagen in a graft, implant, scaffold, or construct consisting of tissue isolated from a mammal and suitable for implantation into a subject for the treatment, repair or replacement of defects or injury in a biological tissue or organ, comprising incubating, prior to implantation into the subject, said graft, implant, scaffold or construct with an agent that breaks, removes, and/or eliminates advanced glycation end-product cross-links in said collagen for a time and at a temperature during which the advanced glycation end-product cross-links in said collagen in said graft, implant, scaffold, or construct are broken, removed, and/or eliminated, followed by rinsing or washing the agent from said graft, implant, scaffold or construct, wherein said agent is no longer present in the graft, implant, scaffold or construct prior to implantation of said graft, implant, scaffold or construct into the subject, and wherein said agent is selected from the group consisting of ALT-462, ALT-486, ALT-946, N-phenacylthiazolium bromide (PTB), TRC4186, TRC4149, C36 and C16.
地址 Ithaca NY US